BMYCelgeneRunning, no new patients
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Multiple Myeloma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 1/2
- Patients
- 424 (planned)
- Started
- Sep 30, 2019
- Main results expected
- Nov 30, 2026
- Fully finished
- Nov 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recommended Dose
Measured over: Up to approximately 3 years
Recommended regimen as measured by dose-limiting toxicities
Measured over: Up to approximately 3 years
Number of participants with Adverse Events (AEs)
Measured over: From first participant first visit until 28 days after the last subject discontinues study treatment, up to 5 years
Overall response rate (ORR)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03989414 · record last updated 2024-11-29 · checked 2026-11-09 15:47 UTC